OBJECTIVES: I. Evaluate the efficacy of fluoxetine on social and language deficits, global severity and compulsive dimensions of children and adolescents with autism. II. Assess the effectiveness of this treatment regimen on neurocognitive deficits in this patient population. III. Compare the baseline compulsive severity and treatment outcome in these patients.

Condition	Treatment or Intervention
Autism	Drug: fluoxetine

Further Study Details: 

Expected Total Enrollment:  50

PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, crossover study. All patients receive oral placebo daily during week 0. Patients are randomized to receive either oral fluoxetine or oral placebo daily on weeks 1-8. Patients then crossover to receive treatment on the other arm during weeks 12-20.

Ages Eligible for Study:  5 Years   -   17 Years,  Genders Eligible for Study:  Both

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Meets diagnostic criteria for autism

--Prior/Concurrent Therapy--

Other:

• At least 3 months since prior electroconvulsive therapy
• At least 1 month since prior investigational drugs or treatment with any drug known to cause major organ toxicity
• At least 2 weeks since prior monoamine oxidase inhibitors
• At least 6 weeks since prior long acting phenothiazines
• At least 1 week since prior other psychotropic drugs
• No prior fluoxetine of 20 mg/day for 6 weeks
• At least 6 weeks since prior fluoxetine
• No concurrent use of terfenadine (Seldane) or astemizole (Hismanal)
• No concurrent electroconvulsive therapy or other psychotropic drugs (unless otherwise permitted)
• Prior participation in another serotonin reuptake inhibitor trial allowed

--Patient Characteristics--

Hematopoietic: No significant hematopoietic disease

Hepatic: No prior or concurrent liver disease

Renal: No prior or concurrent kidney disease

Cardiovascular:

• No significant cardiovascular disease
• No abnormal EKG

Neurological:

• No prior seizure disorder or high risk development of seizures
• No prior cerebrovascular disease
• No prior brain trauma

Other:

• Not pregnant or nursing
• Negative pregnancy test
• No unstable major medical illness or systemic disease
• No moderate or severe mental retardation and motor deficits (IQ less than 50)
• No family history of bipolar disorder
• No prior or concurrent other mental disorders (e.g., schizophrenia, schizoaffective, organic, or bipolar disorders)
• No significant autoaggressive behavior or serious suicidal risk
• No prior or concurrent gastrointestinal conditions
• No unstable endocrine disease (e.g., hypo or hyperthyroidism)
• No prior or concurrent malignancy
• Must be able to tolerate tapering of psychoactive medication
• No history of hypersensitivity or severe side effects to fluoxetine or other serotonin reuptake inhibitors
• No history of severe personality disorder or noncompliance

New York
      Albert Einstein College of Medicine, Bronx,  New York,  10461,  United States; Recruiting
      Mount Sinai School of Medicine, New York,  New York,  10029,  United States; Recruiting
      New York University Medical Center, New York,  New York,  10016,  United States; Recruiting

Study chairs or principal investigators

Eric Hollander,  Study Chair,  Mount Sinai Medical Center   

Study ID Numbers:  199/14266; MTS-FDR001520; MTS-GCO-96-713
Record last reviewed:  December 2000
Last Updated:  October 13, 2004
Record first received:  October 18, 1999
ClinicalTrials.gov Identifier:  NCT00004486
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08